The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday, June 6, 2017.
Valeant in Talks to Sell Surgical Products Business
The Rumor:
Valeant Pharmaceuticals Intl Inc VRX is in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec AG, according to sources as reported by Bloomberg. The business could be worth $2 billion in a sale, the sources said.
Representatives for the two companies declined comment.
Valeant closed at $12.56 on Tuesday, up $0.22.
GTCR, Carlyle Acquire Albany Molecular Research for $21.75/Share
The Deal:
Albany Molecular Research, Inc. AMRI confirmed it has agreed to be acquired by affiliates of The Carlyle Group LP CG and GTCR LLC for $21.75 per share in cash. The deal is expected to close shortly after a vote by AMRI shareholders in Q3 of 2017.
Albany Molecular Research closed at $21.53, up $1.76.
Horizon Pharma Exploring Sale
The Rumor:
Shares of Horzion Pharma PLC HZNP spiked to a high of $11.44 midday Tuesday, on a report from Betaville that the company could be for sale. Horizon acquired Raptor Pharmaceutical in 2016, but failed in a bid to acquire Depomed DEPO.
Horizon Pharma closed at $11.04, up $0.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.